Veeva Systems (VEEV) posted its best-ever single-day gain on Thursday, with the stock jumping 20% to $294.54, after the life sciences cloud software company delivered a clean beat across every key metric in its fiscal second quarter of 2027.

The Pleasanton, California-based company, co-founded in 2007 by former Salesforce technology executive Peter Gassner and publicly traded since 2017, builds cloud software specifically for the life sciences industry, spanning research, clinical, regulatory, and commercial operations. Its original flagship CRM was built on Salesforce’s platform, a partnership that defined Veeva’s first decade in business.

Q2 FY2027 Results

Revenue came in at $928 million, up 18% year-over-year and ahead of the $905 million Wall Street consensus. Adjusted EPS of $2.35 beat the $2.22 estimate, also rising 18% year-over-year.

Non-GAAP operating income reached $415.9 million, ahead of the $395 million estimate and up 18% year-over-year, while non-GAAP net income of $387.4 million topped the $365 million forecast, gaining 16% year-over-year.

Management raised full-year FY2027 revenue guidance to $3.68-$3.69 billion, above the prior analyst consensus of roughly $3.65 billion. Full-year adjusted EPS guidance was lifted to $9.21 from $9.05.

VEEVA SYSTEMS $VEEV Q2’27 EARNINGS HIGHLIGHTS

🔹 Revenue: $928.0M (Est. $905M) 🟢; +18% YoY
🔹 Adj. EPS: $2.35 (Est. $2.22) 🟢; +18% YoY
🔹 Non-GAAP Oper Income: $415.9M (Est. $395M) 🟢; +18% YoY
🔹 Non-GAAP Net Income: $387.4M (Est. $365M) 🟢; +16% YoY

FY27 Guide: 🔹 Revenue:…

— Wall St Engine (@wallstengine), August 26, 2026

Subscription revenue, Veeva’s most closely watched metric, grew 16% year-over-year to $766.8 million and accounts for the bulk of total sales. Non-GAAP operating margins held above 44%, showing that growth is not coming at the expense of profitability.

CEO Peter Gassner said "Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly," referring to the AI agent Veeva built for medical science liaisons, and added that AI is "opening up the next big chapter for Veeva and life sciences."

Two additional top-20 biopharma customers, Eli Lilly and Biogen, committed to Vault CRM during the quarter. That brings the total to 12 of the industry’s top 20 firms on the platform.

Vault CRM runs on Veeva’s own Vault platform rather than the Salesforce infrastructure that powered the original product. The two companies’ long-standing commercial agreement expired in September 2025, and Veeva has committed to supporting remaining Salesforce-based deployments through 2030 while customers complete the shift. Because migrating a global pharmaceutical sales operation onto a new CRM is a multi-year undertaking, each top-20 commitment is watched as a measure of the transition’s progress. Salesforce, for its part, has been pitching its own Life Sciences Cloud to the same customer base.

Nearly 20 analyst firms raised their price targets on the stock following the results, spanning both bullish and more cautious shops.

Analyst Reactions

Barclays analyst Saket Kalia raised his price target to $315 from $275, keeping an Overweight rating, and pointed to the acceleration in subscription revenue as an excellent sign of growth.

Piper Sandler initiated coverage at Overweight with a $295 target. Guggenheim raised its target to $310 from $276, keeping a Buy rating, and called Veeva "indispensable for its customers."

Morgan Stanley analyst Craig Hettenbach raised his target to $275 from $215. He flagged the company’s annual investor day on November 5 as the next key catalyst, calling it "a referendum on the company’s AI strategy."

Even the skeptics took a step toward the bull camp. Canaccord raised its target to $260 from $220 but kept a Hold rating, calling the quarter one of the "cleanest" in some time.

Broader Market Context

The move did not happen in a vacuum. Salesforce jumped more than 20% the same day after topping Q2 expectations and expanding its partnership with Anthropic, while ServiceNow and Datadog also posted sharp gains. Nvidia earnings earlier in the week appeared to reignite appetite for tech and software stocks more broadly.

The Nasdaq gained 1.1% and the S&P 500 added 0.5% on Thursday. Veeva was the second-best performer in the S&P 500 on the day, behind Salesforce.

The stock was in pre-market trading at $264, well above its session open of $239.87, before extending gains as the session progressed.

Veeva’s next major event is its annual investor day on November 5, where management is expected to lay out its AI strategy in detail.

Source: CoinCentral